Regdanvimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Spike protein of SARS-CoV-2 |
| Clinical data | |
| Trade names | Regkirona |
| Other names | CT-P59 |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19.[3] The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.[4][5] The medicine is given by infusion (drip) into a vein.[3][6]
The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.[3]
Regdanvimab was approved for medical use in the European Union in November 2021.[3]
Medical uses[edit]
In the European Union, regdanvimab is indicated for the treatment of adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.[3]
Society and culture[edit]
Names[edit]
Regdanvimab is the proposed international nonproprietary name (pINN).[7]
Legal status[edit]
In March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of data on regdanvimab.[8][9] In October 2021, the EMA started evaluating an application for marketing authorization for the monoclonal antibody regdanvimab (Regkirona) to treat adults with COVID-19 who do not require supplemental oxygen therapy and who are at increased risk of progressing to severe COVID 19.[10] The applicant is Celltrion Healthcare Hungary Kft.[10] The European Medicines Agency (EMA) concluded that regdanvimab can be used for the treatment of confirmed COVID-19 in adults who do not require supplemental oxygen therapy and who are at high risk of progressing to severe COVID-19.[6]
In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for regdanvimab (Regkirona) for the treatment of COVID-19.[11][12] The company that applied for authorization of Regkirona is Celltrion Healthcare Hungary Kft.[12] Regdanvimab was approved for medical use in the European Union in November 2021.[3]
References[edit]
- ^ "AusPAR: Regdanvimab". Therapeutic Goods Administration (TGA). 7 December 2021. Retrieved 4 January 2022.
- ^ "TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona)". Therapeutic Goods Administration (TGA) (Press release). 6 December 2021. Retrieved 4 January 2022.
- ^ a b c d e f g "Regkirona EPAR". European Medicines Agency. Retrieved 12 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform" (Press release). Celltrion. 11 February 2021. Retrieved 4 March 2021 – via Business Wire.
- ^ "Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59" (Press release). Celltrion. 13 January 2021. Retrieved 4 March 2021 – via Business Wire.
- ^ a b "EMA issues advice on use of regdanvimab for treating COVID-19". European Medicines Agency. 26 March 2021. Retrieved 15 October 2021.
- ^ World Health Organization (2020). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)" (PDF). WHO Drug Information. 34 (3): 660–1.
- ^ "EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19" (Press release). European Medicines Agency (EMA). 24 February 2021. Retrieved 4 March 2021.
- ^ "EMA review of regdanvimab for COVID-19 to support national decisions on early use" (Press release). European Medicines Agency (EMA). 2 March 2021. Retrieved 4 March 2021.
- ^ a b "EMA receives application for marketing authorisation Regkirona (regdanvimab) treating patients with COVID-19". European Medicines Agency. 4 October 2021. Retrieved 15 October 2021.
- ^ "Regkirona: Pending EC decision". European Medicines Agency. 11 November 2021. Retrieved 11 November 2021.
- ^ a b "COVID-19: EMA recommends authorisation of two monoclonal antibody medicines". European Medicines Agency (EMA) (Press release). 11 November 2021. Retrieved 11 November 2021.
Further reading[edit]
- Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, et al. (January 2021). "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein". Nature Communications. 12 (1): 288. doi:10.1038/s41467-020-20602-5. PMC 7803729. PMID 33436577.
- Syed YY (December 2021). "Regdanvimab: First Approval". Drugs. 81 (18): 2133–7. doi:10.1007/s40265-021-01626-7. PMC 8558754. PMID 34724174.
External links[edit]
- "Regdanvimab". Drug Information Portal. U.S. National Library of Medicine.
.svg){kind=small}
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |